Natera (NASDAQ:NTRA) CFO Michael Burkes Brophy Sells 37,175 Shares of Stock

Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 37,175 shares of the stock in a transaction on Wednesday, January 21st. The stock was sold at an average price of $242.54, for a total transaction of $9,016,424.50. Following the transaction, the chief financial officer directly owned 64,123 shares in the company, valued at $15,552,392.42. The trade was a 36.70% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Michael Burkes Brophy also recently made the following trade(s):

• On Tuesday, January 20th, Michael Burkes Brophy sold 23,948 shares of Natera stock. The stock was sold at an average price of $234.74, for a total value of $5,621,553.52.
• On Wednesday, October 29th, Michael Burkes Brophy sold 1,867 shares of Natera stock. The stock was sold at an average price of $190.64, for a total value of $355,924.88.
• On Tuesday, October 28th, Michael Burkes Brophy sold 2,415 shares of Natera stock. The shares were sold at an average price of $191.16, for a total value of $461,651.40.
• On Monday, October 27th, Michael Burkes Brophy sold 781 shares of Natera stock. The shares were sold at an average price of $192.32, for a total value of $150,201.92.
• On Friday, October 24th, Michael Burkes Brophy sold 755 shares of Natera stock. The stock was sold at an average price of $196.77, for a total value of $148,561.35.

Natera Stock Up 0.1%

Shares of NTRA stock opened at $242.91 on Friday. Natera, Inc. has a 12 month low of $125.38 and a 12 month high of $256.36. The business’s 50 day moving average is $233.44 and its two-hundred day moving average is $190.60. The company has a market cap of $33.60 billion, a PE ratio of -106.07 and a beta of 1.62.

Natera (NASDAQ:NTRA) last issued its quarterly earnings data on Friday, November 7th. The medical research company reported ($0.64) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.25). Natera had a negative return on equity of 25.07% and a negative net margin of 14.61%.The firm had revenue of $592.18 million during the quarter, compared to analyst estimates of $514.55 million. During the same quarter in the previous year, the firm posted ($0.26) earnings per share. Natera’s quarterly revenue was up 34.7% compared to the same quarter last year. As a group, equities analysts expect that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Hedge Funds Weigh In On Natera

Large investors have recently added to or reduced their stakes in the company. Horizon Investments LLC bought a new stake in shares of Natera in the 3rd quarter worth approximately $32,000. Hilltop National Bank acquired a new position in shares of Natera in the second quarter valued at $33,000. Sound Income Strategies LLC lifted its position in Natera by 95.7% in the third quarter. Sound Income Strategies LLC now owns 225 shares of the medical research company’s stock worth $39,000 after purchasing an additional 110 shares during the period. Flagship Harbor Advisors LLC acquired a new stake in Natera during the fourth quarter worth $41,000. Finally, Quent Capital LLC bought a new stake in Natera in the 3rd quarter valued at $46,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently commented on NTRA shares. Morgan Stanley lifted their price objective on Natera from $220.00 to $265.00 and gave the stock an “overweight” rating in a research note on Monday, December 1st. BTIG Research raised their target price on Natera from $230.00 to $260.00 and gave the company a “buy” rating in a report on Friday, December 5th. Stephens lifted their price target on Natera from $197.00 to $235.00 and gave the stock an “overweight” rating in a research report on Thursday, November 13th. Wells Fargo & Company upped their price target on Natera from $190.00 to $205.00 and gave the stock an “equal weight” rating in a report on Monday, December 15th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Natera in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $245.50.

Key Stories Impacting Natera

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Natera published peer‑reviewed clinical validation of its Latitude™ tissue‑free MRD test for colorectal cancer in npj Precision Oncology — a data milestone that strengthens clinical credibility and could accelerate adoption of a high‑value diagnostic product. Natera Publishes Clinical Validation of Latitude™ Tissue-Free MRD Test in Colorectal Cancer
• Negative Sentiment: CEO Steven Leonard Chapman sold a material block of shares (71,932 shares on Jan 20 and additional smaller sales on Jan 21), reducing his stake by roughly 24.9% from prior levels — a large, high‑profile insider sale that may be viewed negatively by the market. CEO Form 4
• Negative Sentiment: CFO Michael Burkes Brophy disclosed substantial sales (23,948 and 37,175 shares across Jan 20–21), cutting his ownership materially (~36.7% decrease on later filing) — another large insider liquidation that can weigh on near‑term sentiment. CFO Form 4
• Negative Sentiment: Other insiders (John Fesko and Solomon Moshkevich) also sold shares on Jan 20–21 (multiple transactions totaling tens of thousands of shares combined), modestly reducing their stakes. These coordinated/clustered sales increase perceived supply risk. Insider Form 4 example

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.